SEHK:2005Pharmaceuticals
Is NMPA’s Wave Of Drug Approvals Altering The Investment Case For SSY Group (SEHK:2005)?
In late November 2025, SSY Group reported a series of approvals from China’s National Medical Products Administration for new and existing drugs, including treatments for overactive bladder, respiratory diseases, liver-related cholestasis and vitamin A supplementation.
These clustered approvals, many classified as passing China’s consistency evaluation, underline SSY Group’s push to broaden its portfolio of higher-quality, regulated pharmaceutical products in its home market.
We’ll examine...